Search

Investigators are looking at how and why the breast cancer drug trastuzumab sometimes causes long-lasting and potentially serious cardiac side effects.

… Thursday, October 19, 2017 Summary The breast cancer drug trastuzumab, which targets a protein called HER2, can cause long-lasting and potentially serious cardiac side effects. Researchers are using stem cells to study why this happens and to look for ways to prevent it. For people with breast cancer

Learn about how to cope with grief during the holidays from MSK Experts.

… Tuesday, December 13, 2016 Summary MSK experts provide advice on how to cope with grief during the holiday season. It’s important to reevaluate rituals, seek support, and remain aware of your own mental health. Highlights Seek support: Surround yourself with others who’ve experienced what you have. Accept

Expand your knowledge of melanoma with these surprising facts.

… Tuesday, May 11, 2021 Summary Does melanoma always develop from a mole? Can melanoma be pink? Read on to expand your knowledge of the disease. Compared to other cancers, melanoma  may seem fairly straightforward. But there’s more to this disease than meets the eye. Dermatologist Ashfaq Marghoob of the

Adding idelalisib (Zydelig®) to a standard chemotherapy regimen of bendamustine and rituximab (BR) significantly increases progression-free survival (PFS) and overall survival (OS) in patients with relapsed or treatment-resistant chronic lymphocytic leukemia (CLL) as compared with BR alone, according to new findings presented by a Memorial Sloan Kettering (MSK) investigator on behalf of his international co-investigators. Results from the phase III study were presented as part of the press program at this year’s American Society of Hematology annual meeting.

… Sunday, December 6, 2015 Adding idelalisib (Zydelig®) to a standard chemotherapy regimen of bendamustine and rituximab (BR) significantly increases progression-free survival (PFS) and overall survival (OS) in patients with relapsed or treatment-resistant chronic lymphocytic leukemia (CLL) as compared

Neoadjuvant relatlimab and nivolumab achieved high response rates with a favorable safety profile in patients with advanced melanoma, according to initial data from a small clinical trial conducted by researchers at Memorial Sloan Kettering Cancer Center (MSK) and the University of Texas MD Anderson Cancer Center (MD Anderson).

… Wednesday, December 7, 2022 Neoadjuvant relatlimab and nivolumab achieved high response rates with a favorable safety profile in patients with advanced melanoma, according to initial data from a small clinical trial conducted by researchers at Memorial Sloan Kettering Cancer Center (MSK) and the University

Learn about the goals of the Fiona and Stanley Druckenmiller Center for Lung Cancer Research: to reveal more about the biology of lung cancer, to examine novel treatment approaches, and to bring promising new therapies to our patients.

… Thursday, October 1, 2020 Lung cancer causes more deaths in the United States than colon, breast, and prostate cancers combined. Memorial Sloan Kettering launched the Fiona and Stanley Druckenmiller Center for Lung Cancer Research (DCLCR) in 2015 with three primary goals: to reveal more about the biology

Meet three people who were treated as part of a clinical trial for melanoma at Memorial Sloan Kettering.

… Wednesday, February 7, 2018 Summary Behind the incredible discoveries that happen in MSK labs are the equally incredible patients who walk through our doors and bring the science to life. Here, meet three MSK patients who took part in a clinical trial led by surgeon Charlotte Ariyan for the treatment

The global prize is awarded annually to a researcher, physician, or team leader who has made a positive and lasting impact in the fight against pediatric cancer.

… Thursday, May 20, 2021 Memorial Sloan Kettering Cancer Center (MSK) announced that pediatric oncologist A. Thomas Look, MD , of the Dana-Farber / Boston Children’s Cancer and Blood Disorder Center has been named the 2021 recipient of The Society of Memorial Sloan Kettering Prize . The award was presented

With founding partner Equinox, Cycle for Survival surpasses $285 million raised since 2007; every dollar funds rare cancer research led by Memorial Sloan Kettering Cancer Center.

… Monday, June 21, 2021 With founding partner Equinox, Cycle for Survival surpasses $285 million raised since 2007; every dollar funds rare cancer research led by Memorial Sloan Kettering Cancer Center. In the midst of a global pandemic, Cycle for Survival , the movement to beat rare cancers, raised $25

MSK investigators are leading the way with approaches so bold they are like the difference between "a snapshot and a movie."

… Friday, April 1, 2022 VIDEO | 00:25 A Developing Mouse Embryo This movie from the Kat Hadjantonakis lab shows an 11-day-old mouse embryo with its internal organs labeled in different fluorescence. The video was prepared by postdoc Evan Bardot. Video Details To study a complex ecosystem, researchers often